All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
You may also be interested in...
Deal Snapshot: In Almirall’s first de novo artificial intelligence drug discovery and development collaboration, the company will pay up to $650m to work with Absci on two dermatology candidates.
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.